University of Massachusetts Center for Clinical and Translational Science

马萨诸塞大学临床与转化科学中心

基本信息

批准号：
8643314
负责人：
Katherine F Luzuriaga
金额：
$ 338.74万
依托单位：
UNIV OF MASSACHUSETTS MED SCH WORCESTER
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-07-01 至 2015-09-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8643314
关键词：
Award Basic Science Biological Sciences Clinical Clinical Investigator Clinical Research Clinical Sciences Clinical effectiveness Commit Communities Community Outreach Community Participation Core Facility Devices Education Educational Curriculum Faculty Foundations Funding Grant Home environment Institutes Instruction Intervention Investments Laboratories Massachusetts Medicine New England Nobel Prize Patients Phase Physiology Primary Health Care RNA Recruitment Activity Regenerative Medicine Research Schools Scientist Seeds Speed Statutes and Laws Support System System Therapeutic Translational Research Universities Work base bench to bedside career career development dissemination research effectiveness research gene therapy health care delivery implementation research innovation medical schools population based programs stem cell biology translational study

项目摘要

We have established the University of Massachusetts Center for Clinical and Translational Science (UMCCTS) which includes the five UMass campuses. Operationally, the Center is located at the University's Worcester campus and managed by the School of Medicine. The Center serves as the "academic home" for clinical and translational scientists across all UMass campuses. The CTSA program will build clinical and translational research upon a foundation of world class basic science as evidenced by the award of the Nobel Prize in Physiology or Medicine to Craig Mello in 2006 and the Albert Lasker Award to Victor Ambros in 2008. The UMCCTS aims are to: 1) Accelerate early phase translational (Tl) studies by recruiting outstanding T1 research leaders; establishing innovative research core facilities; and developing new therapies, devices, and interventions based upon UMass discoveries; 2) Integrate unique networks of clinical research and healthcare delivery in Central New England and Massachusetts at-large to build and expand T2 (clinical effectiveness research) and T3 (implementation and dissemination research) capacity by recruiting outstanding T2 and T3 research leaders, and by developing innovative T2/T3 core facilities; and enhancing patient and community outreach and participation in clinical/population-based research; 3) The UMCCTS will work collaboratively with all campuses and schools ofthe UMass system in developing programs, curricula, and faculty support systems that promote careers in clinical and translational research. Governor Deval Patrick and the Massachusetts Legislature recently enacted legislation committing $1 billion in state investment to be directed to the Life Sciences in the Commonwealth. With $90 million in seed funding, the University has established the UMass Advanced Therapeutics Cluster (UMATC) which includes the RNA Therapeutics Institute, the Center for Stem Cell Biology and Regenerative Medicine, and the Gene Therapy Center. The UMATC joins the Massachusetts Biologic Laboratories, Meyers Primary Care Institute, and Commonwealth Medicine, four innovative components that are rarely found in academic centers, to speed bench to bedside to community discoveries in clinical and translational research. RELEVANCE (See instructions): The University of Massachusetts Center for Clinical and Translational Science (UMCCTS) will transform the conduct of clinical and translational research by providing an "academic home" for all university clinical investigators. The UMCCTS will provide robust pilot grant programs, comprehensive education and career development programs, and innovative core facilities to support and nurture clinical investigators.

我们已经建立了马萨诸塞大学临床与转化科学中心（UMCCT），其中包括五个UMass校园。在操作上，该中心位于大学的伍斯特校园，由医学院管理。该中心是所有UMass校园的临床和翻译科学家。 CTSA计划将建立临床和授予世界一流基础科学基础的转化研究。诺贝尔生理学或医学奖于2006年授予克雷格·梅洛（Craig Mello）和维克多·安布罗斯（Victor Ambros）在2008年。UMCCT的目的是：1）通过招募加速早期翻译（TL）研究出色的T1研究领导者；建立创新的研究核心设施；并开发新的基于UMass发现的疗法，设备和干预措施； 2）整合临床的独特网络新英格兰中部和马萨诸塞州中部的研究和医疗保健提供，建造和扩展 T2（临床有效性研究）和T3（实施和传播研究）的能力通过开发创新的T2/T3核心设施来招募出色的T2和T3研究领导者；和增强患者和社区外展，并参与基于临床/人群的研究； 3） UMCCTS将与UMass系统的所有校园和学校合作开发计划，课程和教师支持系统，这些系统促进临床和转化研究中的职业。州长迪瓦尔·帕特里克（Deval Patrick）和马萨诸塞州立法机关最近颁布了授予10亿美元的立法在国家投资中，要针对英联邦的生命科学。有9000万美元的种子资金，该大学建立了UMass Advanced Therapeutics Cluster（UMATC），其中包括 RNA疗法研究所，干细胞生物学和再生医学中心以及基因治疗中心。 UMATC加入了马萨诸塞州生物实验室，迈耶斯初级保健研究所，和英联邦医学，四个在学术中心很少发现的创新组件，临床和转化研究中的社区发现的速度替补席位。相关性（请参阅说明）：马萨诸塞大学临床与转化科学中心（UMCCTS）将改变通过为所有大学临床提供“学术住所”来进行临床和转化研究调查人员。 UMCCT将提供强大的试点赠款计划，综合教育和职业开发计划以及支持和培养临床研究人员的创新核心设施。